Innovent Scores Phase 3 Success with Lilly’s Pioneering Obesity Drug for Diabetes Management

Innovent Biologics, Eli Lilly, obesity drug, diabetes management, phase 3 trials, collaboration, metabolic disorders, weight loss, glucose control, next-generation therapy.

Boehringer Ingelheim Leverages Late-Stage Pipeline for 25 New Launches over the Next Decade

Boehringer Ingelheim, Late-stage pipeline, 25 new launches, Decade, Jardiance, Heart failure approvals, Ofev, Pipeline expansion, Management reshuffle

Optimizing Pharmaceutical Supply Chains: The Evolving Role of Third-Party Logistics Providers

Third-Party Logistics (3PL) Providers, Pharmaceutical Supply Chain, Pharma 4.0, Regulatory Compliance, Cold Chain Management, Data Mining and Management, Licensing Requirements

Medicare Partially Covers Weight Loss Drugs Amidst High Price Concerns and Future Negotiation Prospects

Medicare, Obesity drugs, Wegovy, Semaglutide, Price negotiation, Affordability, Accessibility, Premium increases, Utilization management